Q-linea continues to deliver positive signs in turbulent times with a share that has recovered to pre-crisis levels. The earlier signed worldwide partnership and positive results in studies have sparked renewed interest in the share. Our rolled forward risk-adjusted NPV model gives a base case fair value of SEK 87 - with further upside if upcoming trials are successful.